What Happened?
, -based Tyra-Biosciences Resigned Esther van den Boom as Chief Financial Officer
Date of management change: November 02, 2022
, -based Tyra-Biosciences Resigned Esther van den Boom as Chief Financial Officer
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.
Esther van den Boom is Chief Financial Officer at Tyra Biosciences. Previously, Esther held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Padula Natalie, Hoerlein Mary, Petty Cassie, Anderson Jon, McCarthy Gretchen, Grobe Lance, Sahai Narinder, Duwe Ryan, Czarnecki Kevin, Sims Melissa, Patten Clifton
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.